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Abstract (English version) 
 Aim: Weight gain is an important and common side effect of second generation 
antipsychotics (SGAs). Furthermore, these drugs can induce other side effects 
associated with higher cardiovascular morbidity and mortality, such as insulin 
resistance, diabetes or metabolic syndrome. Preliminary studies show that inter-
individual genetic differences produce varying degrees of vulnerability to the different 
SGA-induced side effects. The Second-generation antipsychotic Long-term 
treatment Metabolic side effects (SLiM) study aims to identify clinical, environmental 
and genetic factors that explain inter-individual differences in weight gain and 
metabolic changes in drug-naïve patients after six months of treatment with SGAs. 
Materials and methods: The SLIM study is a multicenter, observational, six-month 
pharmacogenetic study where a cohort of 307 drug-naïve paediatric and adult 
patients (age range 8.8 - 90.1 years) and a cohort of 150 age- and sex- matched 
healthy controls (7.8 – 73.2 years) were recruited. 
Results: This paper describes the rationale, objectives and design of the study and 
provides a description of the sample at baseline.  
Conclusions: Results from the SLiM study will provide a better understanding of the 
clinical, environmental, and genetic factors involved in weight gain and metabolic 
disturbances associated with SGA treatment. 
 
Keywords: Antipsychotic Agents; Weight Gain; Metabolic Syndrome; 
Pharmacogenetics; Drug-Related Side Effects and Adverse Reactions. 
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Abstract (castellano) 
Objetivo: El aumento de peso es un efecto secundario frecuente e importante 
producido por los antipsicóticos de segunda generación (ASGs). Además, estos 
fármacos pueden inducir otros efectos secundarios asociados a un aumento de la 
morbilidad y mortalidad cardiovascular, tales como la resistencia a insulina, la 
diabetes o el síndrome metabólico. Estudios preliminares sugieren que diferencias 
genéticas interindividuales producen distintos grados de vulnerabilidad a los efectos 
secundarios inducidos por los ASGs. El estudio SLIM (por sus siglas en inglés, 
Second-generation antipsychotic Long-term treatment Metabolic side effects) tiene 
como objetivo identificar en pacientes naïve a ASGs, factores clínicos, genéticos y 
ambientales que expliquen las diferencias interindividuales en relación con el 
aumento de peso y los cambios metabólicos generados tras seis meses de 
tratamiento con estos fármacos. 
Material y métodos: El estudio SLIM es un estudio farmacogenético multicéntrico, 
observacional, prospectivo, de seis meses de duración, en el que se ha reclutado 
una cohorte de 307 pacientes pediátricos y adultos (rango de edad 8,8 a 90,1 años) 
naïve a ASGs y una cohorte de 150 controles sanos (rango de edad 7,8 a 73,2 
años) emparejados por edad y sexo. 
Resultados: En este  artículo se presentan la justificación, los objetivos y el diseño 
del estudio y se ofrece una descripción de la muestra al inicio del estudio. 
Conclusiones: Los resultados del estudio SLiM permitirán una mejor comprensión de 
los factores clínicos, ambientales y genéticos implicados en el aumento de peso y 
los trastornos metabólicos asociados al tratamiento con ASGs. 
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Palabras clave: Agentes antipsicóticos; Aumento de peso; Síndrome metabólico; 
Farmacogenética; Efectos secundarios y reacciones adversas a medicamentos. 
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Introduction 
The prescription of second-generation antipsychotics (SGAs) has dramatically 
increased in recent years in pediatric and adult population, both for psychotic and 
non-psychotic disorders1,2. Despite a better extra-pyramidal side effect profile than 
classic antipsychotics, overall, SGAs are associated with a higher prevalence of 
metabolic and endocrine disturbances, such as weight gain, dyslipidaemia or 
glycemic abnormalities3,4. These disturbances lead to a higher risk of cardiovascular 
disease and to an increased morbidity and mortality in these patients, as compared 
with the general population5,6. Furthermore, metabolic adverse events have been 
associated with non-adherence to treatment and poor quality of life7-9. 
Currently, optimization of antipsychotic treatment is limited by the high 
variability of response to treatment and tolerability among individuals. This variability 
is related to clinical heterogeneity, genetic, environmental and social factors10 and 
has hindered the use of pharmacogenomic (PGx) testing or genotype-based 
prescription in clinical practice11,12. However, PGx-related techniques could help the 
identification of patients at higher risk of developing SGA-induced side effects 
through the identification of PGx biomarkers13,14. 
The purpose of the Second-generation antipsychotic Long-term treatment 
Metabolic side effect study (SLiM study), a multicenter, longitudinal, 6-month follow-
up PGx study, was to identify clinical, environmental and genetic predictive factors of 
weight gain and metabolic changes in a Spanish sample of drug-naïve paediatric 
and adult patients treated with SGAs, and a cohort of age- and sex- matched healthy 
controls. The specific goals of the study were: 1) to assess the prevalence of 
anthropometric and metabolic changes after six months of treatment with SGAs, 2) 
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to assess the association between weight gain / metabolic changes and clinical 
improvement / non-adherence to treatment / quality of life, 3) to analyze 
polymorphisms in candidate genes related to appetite control, central nervous 
system homeostatic regulation, and obesity, 4) to assess the association between  
the analyzed genotypes,  weight gain and metabolic changes, and 5) to identify risk 
genotypes that explain inter-individual differences in SGA-induced weight gain and 
metabolic disturbances. 
This paper describes the rationale, objectives and design of the SLiM study 
and provides a description of the sample at baseline. 
Subjects and methods 
 
Recruitment procedure 
From January 2007 to December 2010, seven sites from the Spanish 
Psychiatric Research Network (CIBERSAM) (see www.cibersam.es) recruited a 
sample of 307 paediatric and adult patients consecutively attended in their clinical 
facilities and prescribed an SGA for the first time or with a prior lifetime exposure to 
antipsychotics of no more than 10 days. A cohort of 150 age- and sex- matched 
healthy control subjects was also recruited. Table 1 displays the number of patients 
and controls included in the study per participating site. 
[Place Table 1 about here] 
Patients were recruited from emergency rooms, inpatient units, and outpatient 
clinics. The inclusion criteria for patients were: (i) presence of a psychiatric disorder 
according to DSM-IV criteria15, (ii) capacity to give written informed consent (from 
participants and from their parents or legal guardians when needed), and (iii) being 
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drug- naïve patients (first prescription of an SGA, or, if previously treated, a total 
lifetime exposure to antipsychotics of no more than 10 days). The initial design of the 
SLiM study only considered those patients who were firstly prescribed risperidone, 
olanzapine and quetiapine. Later on, this inclusion criterion was broadened and 
prescription with other SGAs was also allowed. Concomitant treatment with 
stimulants, mood stabilisers, antidepressants, anticholinergic agents, and 
benzodiazepines/hypnotics was also allowed. Presence of a severe medical 
condition was the unique exclusion criterion for patients.  
Healthy controls were recruited among patients’ friends, colleagues and 
neighbors. Inclusion criteria for controls were (i) absence of any psychiatric diagnosis 
according to DSM-IV criteria15 and (ii) capacity to give written informed consent (from 
participants and from their legal guardians/representatives when needed). Exclusion 
criteria for controls were (i) presence of a severe medical condition, and (ii) current 
or past treatment with any antipsychotic drug. The controls were compensated for 
their time with a 25 € gift card at each visit. 
Figure 1 shows a flowchart of the recruitment procedure. Out of the 415 
patients and 153 controls initially identified, 307 patients and 150 controls met the 
inclusion criteria and completed the baseline assessment. Out of these, 163 patients 
and 133 controls completed the 6 month follow-up period. Reasons for drop-out 
were: refusal to continue, loss to follow-up, SGA discontinuation (only for patients), 
death and other reasons (reason was specified). Shift to or addition of a new SGA 
during the follow-up was not considered a reason for drop-out. 
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[Place Figure 1 about here] 
 
Design 
The SLiM study is a prospective, observational, six-month study, in which four 
assessment visits (at baseline, 6 weeks, 3 months and 6 months) were performed for 
patients and controls. At baseline, a complete evaluation (which included recording 
of demographic, diagnostic and clinical data, clinical scales, recording of 
psychopharmacological treatment and side effects, an anthropometric and 
cardiovascular study, and collection of fasting blood and urine samples) was 
performed in the setting where subjects had been recruited. Later on, subjects were 
contacted by telephone and the same assessments were repeated at 6 weeks, 3 
months and 6 months in a psychiatric outpatient setting. A review of the diagnosis 
and of the ongoing pharmacologic treatment, and an assessment of change in global 
psychopathology were also added. Taking the respective anthropometric, 
cardiovascular and blood test data, and based on established criteria, presence of 
insulin resistance16 and presence of metabolic syndrome17-19 were determined at 
each visit. For each participant, after the last completed visit, a completion sheet was 
filled out. Date of last visit and reasons for drop-out (where appropriate) were 
registered. Table 2 summarizes the assessments and their timing throughout the 
study. 
 
[Place Table 2 about here] 
 
 8 
 
Demographic and clinical assessment  
An “ad hoc” protocol for recording of demographic data was designed. Age, 
sex, ethnicity, civil status, educational and occupational level of the participant (or 
his/her parent or legal guardian if under 18 years of age) were recorded. 
Diagnosis was made by experienced psychiatrists according to DSM-IV 
criteria15, by means of a clinical interview and a review of medical records of the 
participant. Also, information on personal medical history (including type 1 and 2 
diabetes mellitus), family history of type 1 and 2 diabetes mellitus and/or 
hyperlipidemia, personal and family history of psychiatric disorder, number and 
duration of hospitalizations (for patients), pregnancy, and substance misuse was 
recorded. Data on somatic and psychopharmacological treatment was also recorded, 
including dosage, dosage changes, and start and discontinuation dates of any 
previous and/or current treatment. Antipsychotic doses were derived to 
chlorpromazine equivalents and current and cumulative doses at each visit were 
calculated20, 21. 
The anthropometric study was performed by trained nurses. Weight (in 
kilograms) and height (in meters) were measured at each visit with the same scale: 
SECA GMBH & Co., Model 797, in Hospital General Universitario Gregorio Marañón 
(HGUGM) and Oviedo Mental Health Service (OMHS); Año Sayol, Model Atlantida, 
in Hospital de la Santa Creu i Sant Pau (HSCSP) and Hospital Universitario Ramón 
y Cajal (HURC); Soenhle  7831 Digital Scale in Hospital Universitario Santiago 
Apóstol (HUSA); Body Composition Analyzer BF-350, Tanita Corporation, in Hospital 
Universitario 12 de Octubre (HU12O); OMROM BF-500 in Hospital Clínico 
Universitario Valencia (HCUV). From this data, body mass index (BMI) was 
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calculated as follows: weight (kilograms) / height (square meters). Because BMI 
varies according to age and sex, the BMI value for these variables was adjusted 
using a conversion to a z-score. For children and adolescents, BMI was adjusted for 
age and sex using Spanish normative charts22. For adults, raw scores were 
transformed to z -scores based on the BMI of the sex-matched control group at each 
visit. Abdominal circumference was measured using a flexible tape measure located 
above the upper edge of the iliac crests. Total body fat mass was measured at each 
visit with the same bioelectrical impedance scale: OMRON BF-500 in HGUGM, 
OMHS, HUSA, HURC and HCUV; OMRON BF-511 in HSCSP; Tanita BF-350 in 
HU12O). At each visit, participants were asked whether they were on diet and 
whether they had experienced changes in appetite and/or in food intake. Information 
on the amount of physical activity (i.e. hours per week of physical activity during last 
week) was also recorded. 
A Cardioline Delta 1 Plus Digital ECG, Versione Base (Renco, Italy) in 
HGUGM, Cardioline AR600ADV ECG (Cavareno, Italy) in OMHS, Philips M1772A 
ECG (Andover, MA, USA) in HSCSP, Philips Page Writer Trim I ECG (Eindhoven, 
The Netherlands) in HUSA, Philips Page Writer TC30 ECG (Andover, MA, USA) in 
HURC, Cardiovit AT-2 ECG, Schiller AG (Baar, Switzerland) in HU12O and Nihon 
Kohden Cardio FAX V Ecaps 12 (Rosbach, Germany) in HCUV were used for the 
ECG assessment. Recording of sitting blood pressure (BP) and heart rate was also 
performed. For children, raw BP values were derived to percentiles according to the 
International Task Force for BP23. 
The Clinical Global Impression- Severity (CGI-S) scale24 and the Clinical 
Global Impression– Improvement (CGI-I) scale24 were completed by experienced 
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psychiatrists. These scales assess severity and improvement, respectively, of global 
symptomatology on a scale of 1 to 7. They are particularly helpful in longitudinal 
studies as they provide an ordinal repeated measure of global clinical status. 
 The Impact of Weight on Quality of Life (IWQOL-Lite) scale25 and the Scale of 
the Udvalg for Kiniske Undersogelser (UKU) scale26 were also administered 
throughout the study by trained psychiatrists. The IWQOL-Lite scale is a 31-item 
self-report scale of obesity-specific quality of life which consists of a total score and 
scores on five subscales (i.e. physical function, self-esteem, sexual life, public 
distress, and work). The UKU scale is a comprehensive rating scale including a total 
of 54 items (divided in four categories) scored 0 to 3, designed to assess general 
side effects of psychotropic drugs. 
 
Biochemical determinations  
Venous blood samples were collected by nursery personnel in 7 
polypropylene EDTA-containing and serum tubes  in the morning (between 8:00 and 
10:00) after fasting overnight and stored initially at 4 ºC. One of the fresh blood 
samples was sent to the Biochemistry Department of each participating site, where 
biochemical determinations were performed. Determinations included lipid profile, 
glucose, glycated hemoglobin A1 (HbA1c), and insulin levels. In all the participating 
sites, blood glucose, total cholesterol, high density lipoprotein (HDL) cholesterol, low 
density lipoprotein (LDL) cholesterol, and triglycerides (TG) were determined by 
enzymatic procedures with an Automatic Chemical Analyzer. HbA1c was analyzed 
by high-performance liquid chromatography (HPLC). Insulin was measured by 
immunoassay with chemiluminescence detection. The Biochemistry Department of 
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each participating site recorded the biochemical data by means of the pre-
established criteria for normality (minimum and maximum) for each parameter. The 
reference values at each site were recorded and individual values were corrected 
and homogenized in the common database. 
For both patients and controls, another blood tube was centrifuged (2000 g x 
10 min, room temperature) after 1 hour of storage. The resultant serum samples 
were carefully collected in serum tubes and stored at ≤ -20ºC until they were sent to 
the Biochemistry laboratory of the coordinating site (HGUGM), where adiponectin 
and leptin levels were determined (in duplicate) by Enzyme-Linked Immune Sorbent 
(ELISA) assay (Human Leptin ELISA [ref: RD191001100], Human Adiponectin 
ELISA [ref: RD195023100]; all Biovendor Laboratory Medicine Inc., Brno; Czech 
Republic). All these determinations were performed by a trained and experienced 
biochemist. 
 
Serum SGA determinations 
For each patient and at each visit, one of the stored serum samples was also 
sent to the Biochemistry laboratory of the coordinating site (HGUGM), where HPLC 
was performed by a trained and experienced biochemist using a Waters 2695 series 
HPLC system (Alliance HPLC system, Waters Corp. Milford, MA, USA). The 
analytes were separated on an Agilent Eclipse XDB C-18 column (150 x 4.6 mm i.d., 
5 m) with a 4.6 x 12.5 mm Eclipse XDB C-18 guard column, following the protocol 
described by Zhang et al27. This semi-quantitative technique provided an indirect 
measure of patient´s adherence to SGAs at each visit (by means of a ‘positive’ or 
‘negative’ HPLC test).  
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Genotype analyses 
For each participant, one of the collected blood samples was stored at ≤ -
20ºC until it was sent to the College of Biology of the University of Barcelona. Here, 
an experienced and trained geneticist performed DNA processing (i.e. coding, 
storage and extraction, using a commercial extraction kit) and DNA genotyping. 
Candidate genes of the SLiM PGx study and their selected SNPs and MAFs are 
summarized in Supplementary Table 1. Candidate genes related to SGA mechanism 
of action, appetite control, homeostatic regulation and weight gain or related 
phenotypes (e.g., obesity) were selected according to previous association and 
genome wide association studies (GWAS) 28-35. Single Nucleotide Polymorphisms 
(SNPs) of these candidate genes were selected according to previous literature and 
the SYSNPS program (www.sysnps.org). SNPs were chosen from the SYSNPS 
program only if they were TagSNPs of the candidate gene and presented a Minor 
Allele Frequency (MAF) > 0.2. This MAF criterion was used to increase the statistical 
power.  
Genotyping was blind to group membership (patient vs. control) and SGA 
treatment. The 5-HTTLPR polymorphism (SLC6A4 gene) was genotyped following a 
standard protocol36. The rs6265 (BDNF gene) and rs1049353 (CNR1 gene) were 
genotyped using Taqman 5’-exonuclease assay. All other SNPs were genotyped by 
competitive quantitative PCR using allele specific probes with FRET signal detection. 
A randomly selected subsample of individuals was re-genotyped in order to confirm 
the pattern of reproducibility.  
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 [Place Table 3 about here] 
 
Urine sampling 
At each visit and for each participant, urine samples were collected and a 
routine urinalysis, pregnancies test (where appropriate) and urine drug tests were 
performed. Amphetamines, cannabis, cocaine, opiates, benzodiazepines and 
barbiturates were determined by immunoassay in HGUGM, HSCSP, HU12O, HUSA, 
and HURC; by endpoint spectrophotometry with monochromatic light in OMHS; and 
by thin-layer chromatography in HCUV.  
 
Metabolic and cardiovascular risk assessment  
Given the respective anthropometric and cardiovascular data, presence of 
metabolic syndrome was established for each patient at each visit. For adult 
participants, metabolic syndrome was defined following the American Heart 
Association/National Heart, Lung, and Blood Institute Scientific Statement19. For 
paediatric participants, metabolic syndrome was defined following an adaptation 
from the criteria by Cook et al., 200317, and Correll and Carlson, 200618. These 
criteria include a clustering of the most relevant risk factors for cardiovascular 
disease: abdominal obesity raised fasting plasma glucose and/or diabetes, abnormal 
lipid profile and high blood pressure (see Table 3). 
Both for pediatric and adult participants, insulin resistance was estimated by 
means of the homeostasis model assessment- insulin resistance (HOMA-IR) index16, 
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which is easily calculated from a single measurement of fasting insulin and glucose 
(see Table 3).  
[Table 3 about here] 
 
Data processing and analysis 
In order to integrate all the available information, and to facilitate data 
management and exploitation, a common database was created. Data entry, 
database design and management were centralized at the coordinating site. 
For the description of the sample at baseline, continuous variables were 
expressed as means, standard deviations (SD) and ranges, and categorical 
variables were expressed as frequencies and percentages. Group differences were 
tested for baseline demographic and clinical data. The comparison groups were 
patients (whole sample) vs. controls (whole sample), paediatric vs. adult patients, 
and paediatric vs. adult controls. Chi-square or Fisher exact tests were used for 
discrete categorical variables. Since all the quantitative variables included in the 
analysis (age, days of previous SGA exposure, current and cumulative doses of 
SGA at baseline) showed non-normal distributions, non-parametric tests (Mann-
Whitney U) were used. Statistical analyses were carried out with the SPSS 18.037 
and differences of p<0.05 were considered significant. All tests were two-tailed. 
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Results 
Sample description at baseline 
The demographic and clinical characteristics at baseline of the 307 (71 
paediatric and 236 adult) patients and 150 (18 paediatric and 132 adult) healthy 
controls who were included in the study are shown in Table 4. Data on SGA and 
concomitant treatments, both in the whole sample and within each age group, are 
also shown in Table 4.  
 
[Table 4 about here] 
 
A significantly higher proportion of patients (47%) than healthy controls (11%) 
dropped out of the study during the follow-up. The main reasons for drop-out are 
shown in Figure 1 and Table 4.  
Discussion  
The SLiM study is the first 6-month prospective, observational, multicenter, 
pharmacogenetic (PGx) study including a large cohort of SGA drug-naïve patients 
across a large age span (8 to 90 years) and with a variety of diagnoses, and a cohort 
of healthy controls matched by age, sex and ethnicity. In our sample, the group of 
paediatric patients had a significantly higher proportion of males, a higher proportion 
of subjects diagnosed with a bipolar disorder and a higher proportion of severe 
patients (defined as having a CGI-S score ≥ 6) than the group of adult patients. 
Irrespective of age, almost 40% of patients were completely naïve to SGAs at 
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baseline. Risperidone was the most commonly prescribed SGA across the entire age 
span. Paediatric patients had higher prescription rates of risperidone, anticholinergic 
agents and stimulants at baseline than their adult counterparts. Conversely, 
olanzapine and antidepressants were more commonly prescribed in adults. Although 
not statistically significant, mean daily doses of prescribed SGAs were slightly lower 
in the paediatric than in the adult group.  
SGAs other than risperidone, olanzapine and quetiapine were scarcely 
prescribed in our sample. This may be partly due to the study design. Initially, only 
those patients who were firstly prescribed with these three SGA drugs were included; 
further on, the inclusion criteria were broadened and prescription of any SGA was 
allowed. This may have biased the results in terms of prescription rates in both age 
groups. Nonetheless, our results were congruent with previous observational studies 
in similar settings, in which these were the most prescribed SGAs, both in 
paediatric38,39 and adult samples40. Except for a patient that had been prescribed 
risperidone for aggression in the context of a conduct disorder and a low intelligence 
quotient, the rest of paediatric patients enrolled in the SLiM study were taking SGA 
drugs for off-label uses. Nonetheless, the fact that olanzapine was poorly prescribed 
in the paediatric group, points towards the increasing awareness of child and 
adolescent psychiatrists around the metabolic profile of this drug41. Regarding 
concomitant treatments, even though antidepressants are increasingly co-prescribed 
with antipsychotics in children and adolescents42,43, co-prescription rates seem to be 
higher in adult population40,44. 
The SLiM study has a number of limitations that are inherent in its naturalistic 
design. Prescribed SGA treatment was not controlled and doses were chosen by the 
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treating psychiatrists, based on clinical criteria. Also, the sample was heterogeneous 
in terms of setting provenance, diagnoses, use of concomitant medications or 
presence of alcohol and substance misuse. This will be taken into account when 
carrying out further analyses of the clinical, environmental, and genetic factors that 
might be associated with weight gain and metabolic disturbances. The main 
difficulties that we encountered were the recruitment of drug-naïve patients and the 
control group matching strategy. That said, a relatively large cohort of drug-naïve 
patients and healthy controls was recruited and followed-up during 6 months. During 
the follow-up, one of the main difficulties that we encountered was the large drop-out 
rate (around 50% of patients and 11% healthy controls dropped out of the study). 
The main reason for drop-out both in adult and paediatric patients was the loss to 
follow-up (19.9% and 32.4%, respectively), while refusal to continue was more 
frequent in adults than in young people (8.5% vs. 1.4%, respectively). 
Discontinuation of the prescribed SGA was a reason for drop-out in around 14% of 
patients (both in adult and paediatric subgroups). Nonetheless, discontinuation rates 
may have been higher, since discontinuation may apply to some of the patients who 
were lost to follow-up or refused to continue participation. Furthermore, the controls 
were compensated with a gift card for their participation in the SLiM study. This may 
have led to a ‘volunteer bias’ (i.e. the bias that comes from the fact that a particular 
sample can contain only those participants who are actually willing to participate in 
the study or experiment45). Nonetheless, the authors tried to control for this by 
means of a careful control group matching strategy. Another relevant limitation is that 
serum SGA determinations at each visit only provide an indirect measure of 
treatment adherence. Nonetheless, these determinations were centralized at one 
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site, where a trained and experienced biochemist performed the analyses following a 
standardized protocol. 
The main strengths of this study include the prospective design of the study, 
with a 6-month follow-up, the homogeneity of the patient and control sample, the 
large age span of the recruited sample and the relatively large sample size 
considering the above mentioned characteristics of the sample. This strategy will 
increase the power of the PGx study with few confounding factors and carry-over 
effects. 
Results from the SLiM study will provide a better understanding of the clinical, 
environmental, and genetic factors involved in weight gain and metabolic 
disturbances associated with SGA treatment. Additionally, we will be able to explore 
the effect of age in such changes and the impact of weight gain in clinical outcome 
and quality of life of drug-naïve patients treated with SGAs. Finally, the study will 
enable the identification of potential PGx biomarkers as predictors for SGA 
tolerability. In the near future, this could potentially assist the individualization of 
antipsychotic treatment and facilitate the development of new therapeutic tools with 
better safety and tolerability profiles. 
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Table 1 Included patients and controls per participating site 
 Patients  Controls 
 N %  N % 
Hospital Universitario Gregorio Marañón 
(HGUGM), Madrid* 120 39.1 
 
53 35.3 
Oviedo Mental Health Services (OMHS), Oviedo 87 28.3  20 13.3 
Hospital de la Santa Creu i Sant Pau (HSCSP), 
Barcelona 45 14.6 
 
19 12.7 
Hospital Universitario Santiago Apóstol (HUSA), 
Vitoria 19 6.2 
 
21 14.0 
Hospital Universitario 12 de Octubre (HU12O), 
Madrid 18 5.9 
 
25 16.7 
Hospital Universitario Ramón y Cajal (HURC), 
Madrid 10 3.3 
 
8 5.3 
Hospital Clínico Universitario de Valencia 
(HCUV), Valencia 8 2.6 
 
4 2.7 
Total 307 100  150 100 
*Coordinating site 
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Table 2 Assessments and timing 
 Baseline 6th week 3rd month 6th month 
Demographic and clinical assessments 
Demographic data X    
Diagnostic (DSM-IV) and clinical interview X X X X 
Medication X X X X 
Family history of diabetes mellitus type 1 and 2 X    
Family history of hyperlipidemia X    
Anthropometric study X X X X 
Cardiovascular study X X X X 
Physical activity X X X X 
Diet, appetite and intake X X X X 
CGI-S scale X X X X 
CGI-I scale  X X X 
IWQOL-Lite scale X X X X 
UKU tolerability scale X X X X 
Blood sampling 
Biochemical/metabolic testing X X X X 
Serum levels of SGA (HPLC) X X X X 
Genetic testing X    
Urine sampling 
Routine urinalysis X X X X 
Pregnancy test (where appropriate) X X X X 
Urine drug testing X X X X 
Metabolic and cardiovascular risk assessments 
Metabolic syndrome X X X X 
HOMA-IR index X X X X 
Completion sheet 
Date of last visit Last completed visit 
Reasons for drop-out (where appropriate) Last completed visit 
Abbreviations: CGI-I: Clinical Global Impression- Improvement; DSM-IV: Diagnostic and statistical manual of mental 
disorders, 4th edition; HOMA-IR: Homeostasis model assessment-estimated insulin resistance; HPLC: High-
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performance liquid chromatography; IWQOL-Lite: Impact of Weight on Quality of Life; SGA: second-generation 
antipsychotic; UKU: Udvalg for Kiniske Undersogelser. 
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Table 3 Criteria for presence of metabolic syndrome and insulin resistance in 
paediatric and adult populations. 
 
 Adult patients Paediatric patients 
Metabolic 
syndrome 
a
≥3 of the following:
 
- Waist circumference ≥ 102 cm in 
males or ≥ 88 cm in females 
- Glucose ≥100 mg/dl 
- Triglycerides ≥150 mg/dl 
- HDL cholesterol <40 in males or 
<50 in females. 
- Blood pressure ≥ 130/85 mmHg 
b,c
≥3 of the following: 
- BMI ≥ 95th percentile or waist 
circumference ≥ 90th percentile 
- Glucose ≥ 100 mg/dl 
- Triglycerides ≥110 mg/dl 
- HDL cholesterol <40 mg/dl 
- Blood pressure ≥ 90th percentile 
HOMA-IR d Fasting glucose (mg/dl) *Insulin (µU/ml)/405 
a Grundy et al., 200519; b Cook et al., 200317; c Correl and Carlson, 200618; d Matthews et al., 198516 
Abbreviations: BMI: body mass index. HDL: high density lipoprotein, HOMA-IR: homeostasis model assessment- 
insulin resistance. 
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Table 4 Demographic and clinical characteristics at baseline of paediatric and adult patients and controls  
 
Patients Controls  
 
Total 
(N=307) 
Paediatric 
(N=71) 
Adult 
(N=236) 
Paed vs. 
adults* 
Total 
(N=150) 
Paediatric 
(N=18) 
Adult 
(N=132) 
Paed vs. 
adults* 
Patients 
vs. 
Controls* 
Age (years), mean (SD), [range] 37.5 (19.9) 
[8.8 – 90.1] 
15.9 (1.6) 
[8.8 - 17.9] 
44.0 (18.4) 
[18.0 – 90.1] 
0.001 34.1 (13.7) 
[7.8 - 73.2] 
15.2 (2.8) 
[7.8 – 17.8] 
36.7 (12.5) 
[18.4 – 73.2] 
0.001 0.556 
Male sex, N (%) 169 (55.0) 49 (69.0) 120 (50.8) 0.007 71 (47.3) 11 (61.1) 60 (45.5) 0.212 0.121 
Ethnicity, N (%) a 
Caucasian 
Hispanic 
Other  
 
260 (85.5) 
25 (8.2) 
19 (6.2) 
 
53 (75.7) 
8 (11.4) 
9 (12.9) 
 
207 (88.5) 
17 (7.3) 
10 (4.3) 
 
0.052 
 
137 (91.9) 
10 (6.7) 
2 (1.3) 
 
13 (72.2) 
3 (16.7) 
2 (11.1) 
 
124 (94.7) 
7 (5.3) 
0 (0) 
 
0.001 
 
0.172 
Diagnosis (DSM-IV criteria), N (%)b 
Schizophrenia spectrum disorders 
Bipolar disorder 
Other psychotic disorders 
Depressive disorders 
OCD 
Other anxiety disorders 
 
42 (14.0) 
28 (9.3) 
108 (36.0) 
35 (11.7) 
1 (0.3) 
9 (3.0) 
 
9 (12.9) 
14 (20.0) 
26 (37.1) 
1 (1.4) 
0 (0) 
0 (0) 
 
33 (14.3) 
14 (6.1) 
82 (35.7) 
34 (14.8) 
1 (0.4) 
9 (3.9) 
 
0.779 
0.001 
0.772 
0.003 
0.999 
0.124 
 
--- 
 
--- 
 
--- 
 
--- 
 
--- 
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Substance disorders 
Adjustment disorders 
Dissociative disorders 
Somatoform disorders 
Eating disorders 
Sleep disorders 
Personality disorders 
Mental retardation 
Autism spectrum disorders 
ADHD 
Conduct disorder/ ODD 
Other infancy/ childhood / adolescence 
Delirium 
Dementia 
9 (3.0) 
14 (4.7) 
2 (0.7) 
3 (1.0) 
1 (0.3) 
3 (1.0) 
16 (5.3) 
3 (1.0) 
2 (0.7) 
5 (1.7) 
2 (0.7) 
1 (0.3) 
10 (3.3) 
6 (2.0) 
0 (0) 
3 (4.3) 
1 (1.4) 
2 (2.9) 
0 (0) 
0 (0) 
5 (7.1) 
0 (0) 
1 (1.4) 
5 (7.1) 
2 (2.9) 
1 (1.4) 
0 (0) 
0 (0) 
9 (3.9) 
11 (4.8) 
1 (0.4) 
1 (0.4) 
1 (0.4) 
3 (1.3) 
11 (4.8) 
3 (1.3) 
1 (0.4) 
0 (0) 
0 (0) 
0 (0) 
10 (4.3) 
6 (2.6) 
0.124 
0.999 
0.410 
0.135 
0.999 
0.999 
0.541 
0.999 
0.410 
0.001 
0.053 
0.231 
0.124 
0.342 
CGI- severity, N (%) c 
Mild (1-3)  
Moderate (4-5) 
Severe (6-7) 
 
26 (9.9) 
201 (76.4) 
36 (13.7) 
 
11 (15.9) 
36 (52.2) 
22 (31.9) 
 
15 (7.7) 
165 (85.1) 
14 (7.2) 
 
0.001 
---    --- 
Treatment status at baseline, N (%) d         - 
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Completely-naïve 
Prior exposure to SGA ≤ 10 days 
Before baseline visit 
In the past 
121 (39.4) 
186 (60.6) 
   184 (59.9)  
         2 (0.7) 
27 (38.0) 
44 (62.0) 
  43 (60.6) 
      1 (1.4) 
94 (39.8) 
142 (60.2) 
   141 (59.7) 
         1 (0.5) 
0.785 --- 
 
--- --- --- --- 
Prescribed SGA at baseline, N (%) e 
Risperidone 
Olanzapine 
Quetiapine 
Other f 
 
126 (41.0) 
77 (25.1) 
88 (28.7) 
16 (5.2) 
 
51 (71.8) 
3 (4.2) 
15 (21.1) 
2 (2.8) 
 
75 (31.8) 
74 (31.4) 
73 (30.9) 
14 (5.9) 
 
0.001 
0.001 
0.109 
0.378 
 
--- 
 
--- 
 
--- 
 
--- 
 
--- 
Previous SGA exposure (days),  mean 
(SD), median, [range] 
2.4 (2.7), 2.0        
[0 – 10] 
2.1 (2.4), 2.0        
[0 – 10] 
2.5 (2.8), 1.5        
[0 – 10] 
0.372 --- --- --- --- ---- 
Current dose of SGA at baseline (mg), 
mean (SD), [range] g 
145.7  (185.7)        
[0 – 1200] 
123.5 (142.1)       
[0 – 530.3] 
152.2 (196.5)       
[0 – 1200] 
0.736 --- --- --- --- --- 
Cumulative dose of SGA at baseline 
(mg), mean (SD) , [range] h 
560.9   
(859.7)        [0 
– 6105.3] 
377.4 (545.8)        
[0 – 2727.3] 
614.8 (926.1)        
[0 – 6105.3] 
0.330 --- --- --- --- --- 
Concomitant treatment, N (%) i          
Antidepressants 
Lithium 
Other mood stabilizers 
Stimulants 
Benzodiazepines 
78 (25.6) 
3 (1.0) 
25 (8.2) 
5 (1.6) 
142 (46.4) 
5 (7.2) 
0 (0.0) 
3 (4.3) 
5 (7.0) 
26 (37.1) 
73 (30.9) 
3 (1.3) 
22 (9.3) 
0 (0) 
116 (49.2) 
0.001 
0.999 
0.185 
0.001 
0.077 
--- --- --- --- --- 
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Anticholinergic agents 12 (3.9) 8 (11.3) 4 (1.7) 0.001 
Drop-out before 6th month assessment, 
N (%)  j 
144 (46.9) 36 (50.7) 108 (45.8) 0.464 17 (11.3) 3 (16.7) 14 (10.6) 0.432 0.001 
Refusal to continue 
Loss to follow-up 
SGA discontinuation 
Death k 
Other reasons 
Unknown 
21 (6.8) 
70 (22.8) 
42 (13.7) 
1 (0.3) 
6 (2.0) 
4 (1.3) 
1 (1.4) 
23 (32.4) 
10 (14.1)  
0 (0) 
2 (2.8) 
0 (0) 
20 (8.5) 
47 (19.9) 
32 (13.6) 
1 (0.4) 
4 (1.6) 
4 (1.6) 
0.034 
0.034 
0.950 
0.999 
0.628 
0.577 
3 (2.0) 
14 (9.3) 
--- 
0 (0) 
0 (0) 
0 (0) 
2 (11.1) 
1(5.6) 
--- 
0 (0) 
0 (0) 
0 (0) 
1 (0.8) 
13 (9.8) 
--- 
0 (0) 
0 (0) 
0 (0) 
0.038 
0.999 
--- 
--- 
--- 
--- 
0.027 
0.001 
--- 
0.999 
0.185 
0.308 
In all cells, % refers to percentages (within columns) of participants for whom information was available. Abbreviations: CGI: clinical global impression; Paed: paediatric; SGA: second-
generation antipsychotic. 
* Statistically significant p-values in bold. For qualitative variables, Chi-square tests (χ2) (Fisher exact test when needed). For quantitative variables, Mann-Whitney U tests. 
a Information available for 304 patients and 149 controls. 
b Information available for 300 patients. Diagnosis refers to the psychiatric condition for which the SGA was prescribed. Forty-five patients had a co-morbid Axis I or Axis II diagnosis 
(data available upon request). ADHD: Attention deficit and hyperactivity disorder. Depressive disorders: major depressive disorder, dysthymia, and depressive disorder not otherwise 
specified. OCD: Obsessive-compulsive disorder. ODD: Oppositional defiant disorder. Other anxiety disorders: generalized anxiety disorder, anxiety disorder not otherwise specified, and 
posttraumatic stress disorder. Other infancy / childhood / adolescence: other disorders of infancy, childhood, or adolescence. Other psychotic disorders: brief reactive psychosis, 
psychotic disorder not otherwise specified, major depressive disorder with psychotic symptoms, substance-induced psychosis, and delusional disorder. Schizophrenia spectrum 
disorders: schizophrenia, schizophreniform and schizoaffective disorder. 
c Information available for 263 patients. 
d Information available for 307 patients. Completely-naïve refers to those patients who were prescribed an SGA for the first time just at the time the baseline visit was performed. Prior 
exposure to SGA ≤ 10 days refers to those patients who had a prior lifetime exposure to antipsychotics of no more than 10 days, either because they had been prescribed an SGA right 
before the baseline visit or in the past. 
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e Information available for 307 patients. Other SGAs: paliperidone (n=6 adult patients), aripiprazol (n=2 paediatric and 4 adult patients), amisulpride (n=2 adult patients), asenapine (n= 1 
adult patient), combination of olanzapine + sulpride (n=1 adult patient). 
h In chlorpromazine equivalents: 100 mg chlorpromazine = about 1.5 mg risperidone / 5 mg olanzapine /  150 mg quetiapine. 
i Information available for 305 patients. 
j Information available for 303 patients and 150 controls. 
k Death was caused by complications of a diagnosed dementia disorder.
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Figure 1 Flowchart for study design 
a Death was caused by complications of a diagnosed dementia disorder. 
Abbreviations: FGA: first-generation antipsychotic; SGA: second-generation 
antipsychotic. 
 
